In a study evaluating the incidence of secondary malignancy in CLL patients receiving ibrutinib treatment, it was stated that CD8 + lymphocyte count reduced the risk of secondary cancer, and that quantitative lymphocyte count could be used as a potential biomarker for the risk of OM.[6] Our data are in agreement with this study. This evidence concerns the gene CD8A and ocular melanoma.